Amicus Therapeutics Inc (FOLD) Actualités

Form 144 - Report of proposed sale of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Amicus Therapeutics Announces Third Quarter 2024 Financial Results and Corporate Updates

Q3 2024 Total Revenue of $141.5M, a 37% Increase Year-over-Year Galafold® Q3 Revenue of $120.4M, up 20...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024

PRINCETON, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that...

Amicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024

PRINCETON, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that...

Form 8-K - Current report

Amicus Therapeutics Announces Settlement of Galafold® (migalastat) Patent Litigation with Teva

PRINCETON, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that it...

Form 4 - Statement of changes in beneficial ownership of securities

Amicus Therapeutics Announces Participation at the World Muscle Society Annual Congress 2024

PRINCETON, N.J., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that...

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities